• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Tel Aviv VC fund aMoon gets $250M from Cred­it Su­isse, emerges as top play­er in Is­rael

7 years ago
Financing

FDA stiff arms Evo­lus' ri­val to Al­ler­gan’s block­buster Botox, but ex­ecs promise a snap re­sponse

7 years ago
Pharma

His way: Greg Ver­dine is build­ing a new kind of drug, with back­ing from a dif­fer­ent kind of in­vestor

7 years ago
Financing

EIP Phar­ma flies in­to a high-risk PhI­Ib Alzheimer’s study fu­eled with $20.5M from bil­lion­aire Len Blavat­nik’s ...

7 years ago
Financing

No­var­tis sac­ri­fices its top at­tor­ney in an at­tempt to quell clam­or over $1.2M in Co­hen pay­ments — while ex-CEO ...

7 years ago
Bioregnum
Opinion

Seat­tle's Nohla clos­es $45M to bring nov­el stem cell treat­ment for leukemia to late-stage tri­als

7 years ago
Financing
Startups

Pfiz­er fi­nal­ly fin­ish­es a 3-year reg­u­la­to­ry odyssey, bag­ging an FDA OK for 1st Epogen knock­off

7 years ago
Pharma

Dai­ichi Sankyo adds $484M pact to its on­go­ing Zymeworks col­lab­o­ra­tion; Sur­face spins out of Im­prim­is with $20M raise

7 years ago
News Briefing

Gilead for­ti­fies its pi­o­neer­ing cell ther­a­py sta­tus, ex­pand­ing in­to three new fa­cil­i­ties and team­ing with NCI

7 years ago
R&D

High pro­file biotech in­vestor Beth Sei­den­berg is ex­it­ing Klein­er Perkins and start­ing her own fund — re­port

7 years ago
People
Financing

Eli Lil­ly touts some mixed PhI­II re­sults for clus­ter headaches as Am­gen, No­var­tis prep a mar­ket-bust­ing move in ...

7 years ago
R&D

Medicxi, RA Cap­i­tal join $30M round for Dutch biotech's late-stage trans­plan­ta­tion med

7 years ago
Financing

Polyphor par­lays a pathogen-spe­cif­ic an­tibi­ot­ic and I/O work in­to a $165M IPO for its PhI­II pro­gram

7 years ago
Financing

Third Rock, GV back Broad spin­out Cel­sius in bid to de­vel­op pre­ci­sion meds for au­toim­mune dis­ease

7 years ago
Financing
Startups

Cam­bridge spin­out Cell­Cen­tric gets $26M for sin­gle-as­set epi­ge­net­ics ap­proach to prostate can­cer

7 years ago
Financing

Wak­sal's gene ther­a­py spin­off MeiraGTx says it’s time to fly with an $86M IPO

7 years ago
Financing

HHS Sec­re­tary Azar pitch­es nam­ing and sham­ing tac­tics on drug price cam­paign, sin­gling out Cel­gene's Revlim­id

7 years ago
Pharma

Tar­get­ing the tricky PI3K path­way in can­cer, MEI gets $75M to push pro­gram through reg­is­tra­tion study

7 years ago
Financing

Chi­na's CStone ramps up yet an­oth­er PD-1 clin­i­cal tri­al for sol­id tu­mors; Take­da faces prof­it de­cline on loss of ...

7 years ago
News Briefing

Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

7 years ago
R&D
Pharma

Eli Lil­ly's on­col­o­gy R&D spree con­tin­ues with $576M deal to buy a start­up and reel back Au­ro­ra A drug

7 years ago
Deals

Blue­bird bio dives deep­er in­to its TCR al­liance with Medi­gene, adding $500M in mile­stones and 2 new tar­gets

7 years ago
R&D
Pharma

CRISPR trail­blaz­ers Zhang, Liu and Joung join forces to launch Beam with $87M and cut­ting-edge gene-edit­ing tech

7 years ago
Financing
Startups

Trump's 'sweep­ing ac­tion' to low­er drug prices mocked by an­a­lysts as re­lieved in­vestors trig­ger ral­ly in Big Phar­ma ...

7 years ago
Pharma
First page Previous page 1027102810291030103110321033 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.